Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: cancer therapeutics - Regen BioPharma

Next Previous
Drug Profile

Research programme: cancer therapeutics - Regen BioPharma

Alternative Names: Checkpoint inhibitor pill - Regen BioPharma; dCellVax™; DiffronC; IDO-silenced cancer immunotherapeutic - Regen Biopharma; IDO-silenced dendritic cell vaccine - Regen Biopharma; NR2F6 inhibitors - Regen BioPharma; NR2F6 T cell immunotherapy; NR2F6-silenced cancer therapeutics - Regen BioPharma; RGBP-248; ucVAX; Universal donor cell therapy - Regen BioPharma

Latest Information Update: 28 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Western Ontario
  • Developer Regen BioPharma; University of Lausanne; University of Western Ontario
  • Class Cancer vaccines; Dendritic cell vaccines; Gene therapies; Small interfering RNA; Small molecules
  • Mechanism of Action Dendritic cell modulators; Gene silencing; Gene transference; Immunostimulants; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Myelodysplastic syndromes
  • No development reported Breast cancer; Colorectal cancer; Leukaemia; Liver cancer

Most Recent Events

  • 28 Mar 2024 No recent reports of development identified for preclinical development in Breast-cancer in USA
  • 20 Jan 2023 Regen BioPharm files a provisional patent protection covering the use of survivin-engineered dendritic cells and exosomes for stimulation of anti-cancer immunity
  • 19 Sep 2022 Regen BioPharma files a provisional patent application for dual checkpoint inhibitor aptamer based therapeutics in the US

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top